

# Seoul International Digestive Disease Symposium 2025

In Conjunction with the Annual Meeting of the Korean Society of Gastroenterology

April 19-20, 2025 | Swiss Grand Hotel Seoul, Korea



SIDDS 2025

## Frontiers in Digestive Research and Practice

<b>Name</b>	Mi Na Kim
<b>Affiliation</b>	Yonsei University College of Medicine
<b>Country</b>	Republic of Korea
<b>Major Field</b>	Liver fibrosis assessment and prognosis in chronic liver disease

### **Educational Background**

M.D., Yonsei University College of Medicine, Seoul, Republic of Korea

Master Degree, Medicine, Graduate School, Yonsei University, Seoul, Republic of Korea

Ph.D., Medicine, Graduate School, Yonsei University, Seoul, Republic of Korea

### **Professional Experience**

Internship, Residency, Fellowship & Clinical research assistant professor, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

Assistant professor & Associate professor, Department of Internal Medicine, CHA University School of Medicine, Seongnam-si, Korea

Postdoc Research Fellow, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, U.S.A.

### **Current position**

Associate professor, Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea



## Frontiers in Digestive Research and Practice

### Main Scientific Publications

1. **Kim MN**, Han JW, An J, Kim BK, Jin YJ, Kim SS, Lee M, et al. KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease. *Clin Mol Hepatol* 2024;30:S5-s105.
2. **Kim MN**, An J, Kim EH, Kim HY, Lee HA, Yu JH, Jin YJ, et al. Vibration-controlled transient elastography for significant fibrosis in treatment-naïve chronic hepatitis B patients: A systematic review and meta-analysis. *Clin Mol Hepatol* 2024;30:S106-s116.
3. Han W, Han K, Hwang SG, Ahn SH, **Kim MN**. Association of physical activity, including amount and maintenance, with the risk of HCC among patients with type 2 diabetes. *JHEP Rep* 2024;6:101166.
4. **Kim MN**, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, et al. ALT Is Not Associated With Achieving Subcirrhotic Liver Stiffness and HCC During Entecavir Therapy in HBV-Related Cirrhosis. *Clin Gastroenterol Hepatol* 2023;21:2278-2287.e2275.
5. **Kim MN**, Han K, Yoo J, Hwang SG, Zhang X, Ahn SH. Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients. *Int J Cancer* 2023;153:1448-1458.
6. **Kim MN**, Kim BK, Roh YH, Choi NR, Yu SJ, Kim SU. Comparable Efficacy Between Ongoing Versus Initiation of Antiviral Therapy at Treatment for HBV-related Hepatocellular Carcinoma. *Clin Gastroenterol Hepatol* 2022;20:1877-1880.e1873.
7. **Kim MN**, Han K, Yoo J, Hwang SG, Ahn SH. Increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis with concurrent fatty liver. *Aliment Pharmacol Ther* 2022;55:97-107.
8. **Kim MN**, Lo CH, Corey KE, Luo X, Long L, Zhang X, Chan AT, Simon TG. Red meat consumption, obesity, and the risk of nonalcoholic fatty liver disease among women: Evidence from mediation analysis. *Clin Nutr* 2022;41:356-364.
9. **Kim MN**, Lo CH, Corey KE, Liu PH, Ma W, Zhang X, Jovani M, et al. Weight gain during early adulthood, trajectory of body shape and the risk of nonalcoholic fatty liver disease: A prospective cohort study among women. *Metabolism* 2020;113:154398.
10. **Kim MN**, Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, Song KJ, et al. Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis. *Hepatology* 2015;61:1851-1859.